TY - JOUR
T1 - Hypermethylation of genes for diagnosis and risk stratification of prostate cancer
AU - Vanaja, Donkena Krishna
AU - Ehrich, Mathias
AU - Van Den Boom, Dirk
AU - Cheville, John C.
AU - Karnes, R. Jeffrey
AU - Tindall, Donald J.
AU - Cantor, Charles R.
AU - Young, Charles Y.F.
N1 - Funding Information:
Wendy Will Case Cancer Fund, Inc., and National Cancer Institute Grant CA091956 supported this work.
PY - 2009/6
Y1 - 2009/6
N2 - To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology. Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer. Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.
AB - To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology. Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer. Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.
KW - CpG site methylation
KW - Mass spectrometry assay
KW - Molecular markers
KW - Prostate cancer
KW - Recurrence prediction
UR - http://www.scopus.com/inward/record.url?scp=67449097913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67449097913&partnerID=8YFLogxK
U2 - 10.1080/07357900802620794
DO - 10.1080/07357900802620794
M3 - Article
C2 - 19229700
AN - SCOPUS:67449097913
SN - 0735-7907
VL - 27
SP - 549
EP - 560
JO - Cancer Investigation
JF - Cancer Investigation
IS - 5
ER -